AB Science S.A. | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
14,611.00
16,112.00
26,716.00
27,696.00
27,122.00
26,061
Depreciation, Depletion & Amortization
329.00
438.00
392.00
611.00
436.00
669
Other Funds
1,423.00
645.00
430.00
1,848.00
1,282.00
2,444
Funds from Operations
12,859.00
16,319.00
26,754.00
28,933.00
27,968.00
27,836
Changes in Working Capital
220.00
2,201.00
3,513.00
4,701.00
5,080.00
1,038
Net Operating Cash Flow
12,639.00
14,118.00
23,241.00
33,634.00
22,888.00
26,798
Capital Expenditures
433.00
663.00
618.00
524.00
503.00
Purchase/Sale of Investments
7,171.00
846.00
19.00
6,000.00
-
Net Investing Cash Flow
6,738.00
1,509.00
637.00
5,476.00
503.00
Issuance/Reduction of Debt, Net
11,226.00
1,886.00
2,805.00
143.00
-
Net Financing Cash Flow
21,068.00
1,945.00
26,425.00
32,250.00
42,371.00
Net Change in Cash
15,196.00
13,744.00
2,499.00
4,084.00
19,009.00
Free Cash Flow
12,790.00
14,252.00
23,329.00
33,703.00
23,341.00
Change in Capital Stock
9,842.00
59.00
23,620.00
32,393.00
42,371.00
Exchange Rate Effect
29.00
62.00
48.00
8.00
29.00

About AB Science

View Profile
Address
3, Avenue George V
Paris Ile-de-France 75008
France
Employees -
Website http://www.ab-science.com
Updated 07/08/2019
AB Science SA engages in the research, development, and sales of protein kinase inhibitor drugs. It develops pharmaceutical products for the treatment of cancer, neurological, and inflammatory diseases. The firm also engages in the field of veterinary medicine.